NuvaHealth vs SkinnyRx
NuvaHealth and SkinnyRx both sell semaglutide and tirzepatide; this is how their prices, coverage and records differ.
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
NuvaHealth
Best for: seeing what it charges before you answer any medical questions
Visit NuvaHealth →
If you are choosing between NuvaHealth and SkinnyRx, price alone will not settle it. Both prescribe semaglutide and tirzepatide, so moving from one to the other would not change your drug. NuvaHealth leads our six-part score, 6.4 to 5.9. One of the two has an FDA warning letter on record, covered below.
NuvaHealth vs SkinnyRx price
NuvaHealth only publishes an introductory price, $139 for the first month, and does not say what month two costs. SkinnyRx lists $149.25 a month. Until NuvaHealth posts a standing rate, the two numbers are not a like-for-like comparison.
Drug by drug: Semaglutide is cheaper at NuvaHealth ($139 for the first month vs $149.25 a month); tirzepatide is cheaper at SkinnyRx ($224.25 a month vs $229 for the first month).
Medications and formats
Both sell semaglutide and tirzepatide.
On format, NuvaHealth prices compounded injections, an oral option and brand-name pens, while SkinnyRx prices compounded injections and an oral option.
If you want the FDA-approved brand rather than a compounded version, NuvaHealth is the only one of the two with a brand-name price.
Where each one treats patients
Neither NuvaHealth nor SkinnyRx publishes the states it serves, so enter your state at the very start of each sign-up.
Pricing
NuvaHealth
first month; ongoing price shown at checkout (month two)
first month; ongoing price shown at checkout (month two)
first month; ongoing price shown at checkout (month two)
first month; ongoing price shown at checkout (month two)
first month; ongoing price shown at checkout (month two)
first month; ongoing price shown at checkout (month two)
first month; ongoing price shown at checkout (month two)
SkinnyRx
'As low as $149.25/mo*' — plan-length/promo dependent (matches the sitewide '25% lower prices' promo, $199 x 0.75); standard single-month rate not published pre-intake. Microdose available; free overnight shipping.
'As low as $199/mo*' on /products/semaglutide-oral; once-daily.
'As low as $249/mo*' on /products/semaglutide-tablets.
'As low as $224.25/mo*' and 'Starting at $224.25/mo with free overnight shipping'; microdose available; once-weekly.
'As low as $224.25/mo*' on /products/tirzepatide-tablets; once-daily.
'$1,400/mo*' — '*Price shown applies to Monthly plan paid upfront or with buy now, pay later programs.' 'No membership fees. Same price at every dose.'
'$1,400/mo*' on /products/wegovy-injectable. Wegovy PILL is listed 'Unavailable' ('available via SkinnyRx Membership', fee not published).
'$1,400/mo*' on /products/mounjaro.
'$1,400/mo*' on /products/zepbound. Foundayo (orforglipron) pill also listed but 'Unavailable' — price not published.
What each price covers
Both prices cover the medication itself and shipping.
SkinnyRx's price also covers the clinician visit, which NuvaHealth does not claim.
NuvaHealth is silent on the clinician visit, lab work and coaching.
SkinnyRx is silent on lab work and coaching.
NuvaHealth
Covered by the monthly price
Medication
In the price
Clinician visits
Not stated
Shipping
In the price
Lab work
Not stated
Coaching
Not stated
SkinnyRx
Covered by the monthly price
Medication
In the price
Clinician visits
In the price
Shipping
In the price
Lab work
Not stated
Coaching
Not stated
Where each one scores higher
Overall, NuvaHealth scores 6.4 and SkinnyRx 5.9 out of 10.
NuvaHealth is stronger on user experience (8.0 vs 3.0) and trust & safety (6.5 vs 1.0).
SkinnyRx is stronger on value (6.5 vs 3.0) and support (7.0 vs 4.5).
Effectiveness and accessibility are within half a point.
NuvaHealth
6.4/10
SkinnyRx
5.9/10
Value25%
Effectiveness25%
User Experience15%
Trust & Safety15%
Accessibility10%
Support10%
FDA warning letters
The FDA sent SkinnyRx a warning letter dated February 20, 2026 (letter 717989), and it is still open.
NuvaHealth has no FDA warning letter on record with us.
Features & Coverage
| Feature | NuvaHealth | SkinnyRx |
|---|---|---|
| Starting Price | $139 first month | $149.25/mo |
| Features | ✓5 features | 3 features |
| States Available | Not disclosed | Not disclosed |
| Compounded | ✓ Yes | ✓ Yes |
| Brand Name | ✓ Yes | — |
| FSA/HSA Accepted | — | — |
| FDA Warning Letters | ✓None | 1 letter |
About NuvaHealth
NuvaHealth advertises compounded semaglutide from $159 and compounded tirzepatide from $259, both first-month figures; standard ongoing pricing is disclosed at checkout after the medical intake. The program covers an online medical consultation, free shipping and 24/7 patient support, and the platform is LegitScript-certified. A Newark, DE address is listed. It does not disclose a specific legal entity name on the home page.
Read our full NuvaHealth review →About SkinnyRx
SkinnyRx sells compounded semaglutide and tirzepatide as injectables, with a microdosing option, prescribed by licensed US clinicians. The consult and free overnight shipping are bundled into a single monthly cash price.
Read our full SkinnyRx review →Pros & Cons
NuvaHealth
What we like
- Shows its price before the medical questionnaire, so you can compare it without handing over health information
- The monthly price includes the medication and shipping
- We found no FDA warning letters issued to NuvaHealth
Watch-outs
- Confirm it serves your state before you start the intake
- Ask which pharmacy fills the prescription before you pay, so you can check its license
- Its semaglutide and tirzepatide are compounded rather than FDA-approved, so they have not been reviewed by the agency for safety, effectiveness or manufacturing quality
SkinnyRx
What we like
- Semaglutide costs $149.25 a month, 19% below the $184 median for compounded semaglutide across the sellers we compare
- Tirzepatide costs $224.25 a month, 10% below the $250 median for compounded tirzepatide across the sellers we compare
- The monthly price includes the medication, clinician visits and shipping
- Offers both oral and injectable options, so the format is your choice
Watch-outs
- You only see a price after finishing the medical intake, so you cannot compare costs before sharing health information
- Confirm it serves your state before you start the intake
- Ask which pharmacy fills the prescription before you pay, so you can check its license
- The FDA has issued SkinnyRx a warning letter. Read what it alleges: a letter flags a problem but does not by itself rule a seller out
- Its semaglutide and tirzepatide are compounded rather than FDA-approved, so they have not been reviewed by the agency for safety, effectiveness or manufacturing quality
Our Verdict
SkinnyRx is where we would start, above all for starting below a standard dose, with microdose tiers. NuvaHealth fits better if seeing what it charges before you answer any medical questions is your priority.
Choose NuvaHealth if…
You want seeing what it charges before you answer any medical questions.
Choose SkinnyRx if…
You want starting below a standard dose, with microdose tiers and an opening price near $149.25 a month.
Ready to start? GLP-1 providers we have vetted
Telehealth providers, vetted by us, prescribing GLP-1 online.
Vetted by our editors · no insurance required
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Sesame Care
Oral orforglipron alongside the injectables
From $59/mo
Get started →Collective
Flat any-dose pricing, if you can absorb a $199 annual membership on top
From $59/mo
Get started →Found
Tirzepatide at $169/month, 37% below the typical price
From $149/mo
Get started →NuvaHealth vs SkinnyRx: FAQ
Close alternatives to NuvaHealth and SkinnyRx
- NuvaHealth vs Ark Health
- NuvaHealth vs Healthicare
- NuvaHealth vs Eve
- NuvaHealth vs Good Girl Rx
- SkinnyRx vs MedLeanRx
- SkinnyRx vs Rivo Health
Or see the full category ranking.
Novo Nordisk A/S owns the Wegovy®, Ozempic® and Rybelsus® marks; Eli Lilly and Company owns Mounjaro® and Zepbound®. Every other product name and mark on this page belongs to whoever owns it. No pharmaceutical manufacturer is affiliated with GLP Watchdog. See trademark disclaimer.